Apr 20 |
Favourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired Stock
|
Apr 11 |
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
|
Apr 9 |
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
|
Mar 12 |
Cadrenal Therapeutics files for $100M mixed shelf
|
Mar 11 |
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update
|
Feb 26 |
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
|
Feb 8 |
Cadrenal Therapeutics appoints Jeff Cole as COO
|
Feb 8 |
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
|
Jan 31 |
Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions
|
Jan 30 |
Here's Why We're Not Too Worried About Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation
|